Henderson Berg Meagan-Helen, Carrasco Daniel
J Drugs Dermatol. 2017 Jul 1;16(7):695-698.
Psoriasis is a chronic inflammatory cutaneous disease that affects 2-3% of the general population. Up to 30% of patients with psoriasis also develop psoriatic arthritis, a chronic inflammatory and progressive arthritis. Although their precise pathogeneses remain unclear, psoriasis and psoriatic arthritis involve altered expression of proinflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-12, IL-17, IL-22, and IL-23. The development of biologic agents that target these cytokines has greatly improved the treatment of psoriatic disease. Injection site reactions have been reported with many of these therapies. In this paper, we will present cases and review the literature on injection site reactions with the major biologic agents administered subcutaneously for the treatment of psoriasis and psoriatic arthritis.
J Drugs Dermatol. 2017;16(7):695-698.
.银屑病是一种慢性炎症性皮肤病，影响着2%至3%的普通人群。高达30%的银屑病患者还会发展为银屑病关节炎，这是一种慢性炎症性进行性关节炎。尽管它们的确切发病机制尚不清楚，但银屑病和银屑病关节炎涉及促炎细胞因子表达的改变，包括肿瘤坏死因子-α、白细胞介素（IL）-12、IL-17、IL-22和IL-23。靶向这些细胞因子的生物制剂的开发极大地改善了银屑病的治疗。许多这类疗法都报告了注射部位反应。在本文中，我们将展示病例并回顾关于皮下注射用于治疗银屑病和银屑病关节炎的主要生物制剂的注射部位反应的文献。
《皮肤药物学杂志》。2017年；16(7):695 - 698。
